RetaMaps

TruBalance Health Little Rock

TruBalance Health Little Rock · 12911 Cantrell Road · Little Rock, AR 72223

4.9· 22 Google reviews

Listing updated October 2, 2026

Retatrutide outlook for this practice

No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.

Care described on the practice's website

  • Medically supervised weight loss

About this practice

TruBalance Health in Little Rock, Arkansas, is a weight-loss clinic that, per its website, develops customized health plans for each client. Its site introduces Dr. Traci Kiernan as a wellness physician, health coach, author and radio show host, and mentions monthly live access to her for updated information. On Google it holds a 4.9-star rating across 22 reviews dating back to 2019, though none were posted in the past year; reviewers most often mention results and the staff, with a few noting the team's knowledge and billing.

Services & access

Advertises semaglutide todayNot listed
Advertises tirzepatide todayNot listed
Telehealth visitsNot listed
Cash pay accepted—
Accepts insurance — per practice websiteYes
Accepting new patients — per practice websiteYes

"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.

Review activity

★ 4.9
Google rating · 22 reviews
5
reviews mention weight loss

Counts computed by RetaMaps from public Google reviews; most recent review 2025-01-03. Read the reviews themselves on the practice's Google listing.

What patients say

Rated ★4.9 across 22 Google reviews. Of the 22 reviews we analyzed, 21 (95%) are positive (4–5★) and 0 (0%) are negative (1–2★).

What patients like

  • Weight-loss results7 reviews
  • Friendly, helpful staff6 reviews
  • Consistent follow-up and check-ins3 reviews

Common complaints

No negative reviews among those we analyzed.

5★
20
4★
1
3★
1
2★
0
1★
0

Most recent Google reviews

denise n.★★★★★2025-01-03

Could people please share recent reviews for TruBalance in Little Rock. All reviews are about 4 years old!

Lora T.★★★★★2022-10-03

I cannot praise Trubalance even for all their help in my new lifestyle journey!

Cindy P.★★★★★2021-03-24

Awesome way to learn to heal your body!

Barbara V.★★★★★2020-07-19

I have been so fortunate to have found true Balance and a very healthful way to live. At 78 I got re-educated on the way to eat and live. Now almost two years in I’m in the best health ever.

Leah H.★★★★★2020-07-18

The TruBalance program has been nothing but GREAT for me! It isn't only about weight loss. It has helped me understand how to fuel my body, rather than feeding it. There is constant support and the staff is polite and helpful.

Analysis by RetaMaps of reviews on this practice's public Google Business listing; review themes are detected automatically and reviews reflect their authors' opinions. See all reviews on Google.

Nearby providers in Little Rock

Retatrutide status
Phase 3 complete · Not FDA-approvedUpdated October 2, 2026

Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.

Development
Phase 3 complete
FDA status
Submission planned — Q1 2027 (Lilly guidance)
Availability
Not commercially available
Access routes
Clinical trials, or Lilly's expanded access program (physician must apply)

Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)

Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs